好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2015 Annual Meeting | 5HC.002 - Autism Spectrum Disorders - What We Know and Where We Are Going

Wednesday 04/22/15
02:00 PM - 06:00 PM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Half-Day Course
Max Wiznitzer, MD, FAAN
Participants should be able to understand the diagnostic criteria for and comorbidities of autism spectrum disorders (ASD) and how they guide research and intervention; know the genetic basis and associated body pathways for ASD and how they affect brain structure and function and potentially influence present and future research and intervention; and recognize issues and medical problems that impact individuals with ASD during the transition to adult and throughout the rest of the lifespan.
3.75 CME credits
Trainee, General Neurologist, Specialist Neurologist, Advanced Practice Provider
Didactic
Event Timeline
02:00 PM - 02:50 PM Autism Spectrum Disorders: Symptom Structure, Diagnosis, Comorbidity and Resilience
John Constantino
02:50 PM - 03:40 PM Autism Spectrum Disorders: Genetics and Neurobiology
Daniel H. Geschwind, MD, PhD
03:40 PM - 03:55 PM Break
03:55 PM - 04:40 PM Autism Spectrum Disorders: Structural and Functional Neuroimaging
Susan Y. Bookheimer, PhD
04:40 PM - 05:30 PM Autism Spectrum Disorders: Management over the Lifespan: Present and Future
Max Wiznitzer, MD, FAAN
05:30 PM - 06:00 PM Questions and Answers
Faculty Disclosures
Max Wiznitzer, MD, FAAN Dr. Wiznitzer has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Department of Health and Human Services - Vaccine Injury Compensation Program. Dr. Wiznitzer has a non-compensated relationship as a Board of Directors with CHADD that is relevant to AAN interests or activities.
Susan Y. Bookheimer, PhD No disclosure on file
John Constantino No disclosure on file
Daniel H. Geschwind, MD, PhD Dr. Geschwind has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Ovid Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for AcuraStem, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Axial Biotherapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Falcon Computing. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier-Biological Psychiatry. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NYAS. Dr. Geschwind has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Covington& Burling LLP. Dr. Geschwind has stock in none related to talk. The institution of Dr. Geschwind has received research support from CurePSP. The institution of Dr. Geschwind has received research support from NINDS. The institution of Dr. Geschwind has received research support from Rainwater Charitable Foundation. The institution of Dr. Geschwind has received research support from NIMH. The institution of Dr. Geschwind has received research support from NINDS. The institution of Dr. Geschwind has received research support from NIH. The institution of Dr. Geschwind has received research support from The Simons Foundation. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from Adelson Medical Research Foundation. The institution of Dr. Geschwind has received research support from NINDS. The institution of Dr. Geschwind has received research support from NIMH. The institution of Dr. Geschwind has received research support from NINDS/NIA. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from Adelson Medical Research Foundation. The institution of Dr. Geschwind has received research support from NIH/NINDS. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from Adelson Medical Research Foundation. The institution of Dr. Geschwind has received research support from U of Virginia and NIH/NIMH. The institution of Dr. Geschwind has received research support from NIH. The institution of Dr. Geschwind has received research support from NIH/NHGRI. The institution of Dr. Geschwind has received research support from NIH/NIMH. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care.